StreetInsider.com News Articles

Cerenome unit secures Florida Blue payer deal for CNS tests

Thu, 08 Oct 2026 07:31:08 -0400

Cerenome, Inc. (Nasdaq: CNSY) announced that its subsidiary CNSide Diagnostics, LLC has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.

The agreement covers contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test and CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. According to the company, it is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling.

The Florida Blue deal adds approximately 6 million covered lives to CNSide's contracted payer network. Combined

Cerenome unit secures Florida Blue payer deal for CNS tests

Thu, 08 Oct 2026 07:31:08 -0400

The Florida Blue deal adds approximately 6 million covered lives to CNSide's contracted payer network. Combined

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Thu, 08 Oct 2026 07:30:00 -0400

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration

Expands CNSide contracted payer access to approximately 164 million covered lives

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.

The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Thu, 08 Oct 2026 07:30:00 -0400

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration

Expands CNSide contracted payer access to approximately 164 million covered lives

The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid

Cerenome Launches CNSide® CSF Molecular Profile Tests

Tue, 06 Oct 2026 07:30:00 -0400

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA)
CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more

Cerenome Launches CNSide® CSF Molecular Profile Tests

Tue, 06 Oct 2026 07:30:00 -0400

CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA)
CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more

Form 8-K CERENOME, INC. For: Oct 02

Fri, 02 Oct 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20261002/27138832.html

Cerenome (CNSY) PT Lowered to $31 at Lake Street

Thu, 01 Oct 2026 08:51:54 -0400

Lake Street analyst Chad Messer lowered the price target on Cerenome (NASDAQ: CNSY) to $31.00 (from $50.00) while maintaining a Buy rating.

Form 4 CERENOME, INC. For: Oct 01 Filed by: ANDREWS RONALD ASBURY